Company intelligence / Profile preview

Choice Therapeutics

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

YCT-529 demonstrated strong safety profile in phase 1a study with no effect on sexual desire or mood. Preclinical studies showed 99% efficacy and 100% reversibility in mice, with performance comparable to or better than female birth control pills. Phase 1b/2a trial currently underway in New Zealand[2].

Therapeutic areas: Men's Health
Modalities: Small molecule
Industry: Biotech

Partnerships

Male Contraceptive Initiative (MCI)Quotient Sciences (Phase 1a study)NZCR (Phase 1b/2a study)Dr. Gunda Georg (medicinal chemistry collaboration)[2]

Beyond the preview

Go deeper on Choice Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Choice Therapeutics.

Explore the full profile